TGA (Australia)Therapeutic Goods Administration

The Therapeutic Goods Administration (TGA) is the Australian Government regulatory authority for therapeutic goods. It is part of the Australian Government Department of Health, Disability and Ageing and operates under the Therapeutic Goods Act 1989 (TG Act), the Therapeutic Goods Regulations 1990, the Therapeutic Goods (Medical Devices) Regulations 2002, and the body of Therapeutic Goods Orders (TGOs) covering specific product types + standards.

TGA's regulatory scope covers prescription medicines, over-the-counter (OTC) medicines, complementary medicines (vitamins + minerals + herbal + traditional + homeopathic), medical devices including IVDs, biologicals (human cell + tissue products) under the Biologicals Framework, blood + blood components, and a range of other therapeutic goods. TGA does not regulate cosmetics in most cases (unless they make therapeutic claims), nor most foods (which are regulated by FSANZ in Australia + New Zealand).

Australian therapeutic-goods regulation operates the Australian Register of Therapeutic Goods (ARTG) — the central national register. Goods must be entered on the ARTG before supply: as Registered (R, including AUST R for medicines + the device-specific ARTG entry for medical devices) for higher-risk products requiring full pre-market evaluation, or as Listed (L, AUST L for low-risk medicines + AUST L(A) for assessed listed medicines with limited claims) for lower-risk products. Devices are entered after conformity assessment matched to risk class.

TGA is a permanent PIC/S member (founding member 1995), a founding MDSAP regulator alongside Health Canada + FDA + ANVISA + PMDA, a member of the ICMRA + ACSS Consortium (Australia + Canada + Singapore + Switzerland + UK collaboration), and one of the seven Reference Regulators recognised by MHRA's International Recognition Procedure from 1 Jan 2024.

All therapeutic goods supplied in Australia must have an Australian Sponsor — an entity established in Australia (or with an authorised representative established in Australia) that takes legal + regulatory responsibility for the product. The Sponsor:

• Holds the ARTG entry + is the legal entity on which TGA enforcement actions are taken.
• Is responsible for compliance with the Therapeutic Goods Act + the conditions of inclusion on the ARTG.
• Submits applications, variations, annual entries, and post-market reports.
• Operates the post-market pharmacovigilance + vigilance program for the product.
• Manages product recalls + corrective + preventive actions under TGA's URPTGA (Uniform Recall Procedure for Therapeutic Goods).
• Maintains the Australian product information (PI), consumer medicine information (CMI), and labelling per the applicable TGOs.

Non-Australian manufacturers typically either establish an Australian subsidiary that holds the ARTG entry, or contract with an Australian-based Sponsor (a third-party Sponsor of Record, conceptually similar to the Japanese DMAH or the EU MAH). Choice has significant strategic, tax + IP implications.

Australian medical devices are classified using a risk-tier framework substantively aligned with the EU MDR + IMDRF principles.

• Class I — Lowest risk (e.g. surgical drapes, gauze).
• Class IIa — Low-medium risk (e.g. hearing aids, dental fillings).
• Class IIb — Medium-high risk (e.g. ventilators, infusion pumps).
• Class III — Highest risk (e.g. cardiovascular catheters, implantable hip prosthesis).
• Active Implantable Medical Devices (AIMD) — separately classified; comparable to Class III (e.g. pacemakers, implantable defibrillators).
• IVDs — Class 1-4 risk tiers separately defined.
• Class I sterile / measuring / reusable surgical instrument — uplifted to additional conformity assessment requirements.
• Conformity assessment — manufacturer chooses between TGA-issued Conformity Assessment Certificate, or a Conformity Assessment certificate from a TGA-recognised Designated Notified Body (e.g. EU Notified Body recognised by TGA), or an MDSAP audit certificate (accepted for the QMS portion for Class II+ devices) plus the relevant additional product-related conformity assessment.
• Class III + AIMD + Class 4 IVD — additional TGA application audit required, including review of clinical evidence per TGA's clinical evidence guidance.
• Inclusion on the ARTG — after successful conformity assessment, the Sponsor applies for ARTG inclusion using the TGA Business Services portal.
• AusUDI — Australian Unique Device Identifier implementation under the 25 Feb 2021 rules; phased transitions through 2026-2030; recognition of GS1, HIBCC, and ICCBBA issuing agencies aligned with IMDRF + FDA + EU.

• TGA Manufacturing Licence — required for any Australian site that manufactures medicines, biologicals, or certain device categories.
• TGA GMP Clearance — required for any non-Australian manufacturing site supplying the Australian market; obtained via three routes: (a) MRA pathway — GMP certificate from an MRA partner regulator (EU, Switzerland, others) accepted; (b) Compliance Verification (CV) pathway — TGA review of recent PIC/S-member regulator GMP inspection outcome (most common for non-MRA-partner regulators); (c) TGA on-site inspection — for sites without an acceptable recent inspection outcome.
• PIC/S GMP — TGA enforces the PIC/S GMP guide for medicines + APIs, substantively aligned with EU GMP Parts I + II + the Annexes including Annex 1 (sterile, 2022 revision in force 25 Aug 2023), Annex 11 (computerised systems), Annex 15 (qualification + validation), Annex 16 (certification + release).
• Biologicals — separate Biologicals Framework under Therapeutic Goods (Manufacturing Principles) Determination 2018 with specific Class 1-4 biological-product manufacturing controls.
• Medical Device GMP — TGA Conformity Assessment includes a QMS audit against ISO 13485 + Australian-specific requirements; MDSAP certificate is an acceptable alternative for the QMS portion for Class II+ devices, substantially reducing duplicate-audit burden.
• Manufacturing principles update — Therapeutic Goods (Manufacturing Principles) Determination updates incorporate the latest PIC/S GMP guide editions.
• Recalls + non-compliance — TGA Inspectorate uses URPTGA + market action including cancellation of ARTG entry, suspension of Manufacturing Licence, infringement notices + prosecution.
• Data integrity — TGA Inspectorate enforces ALCOA+ aligned with the MHRA 2015 + WHO + PIC/S Annex 11 expectations.

• Australian Pharmacovigilance Responsibilities Guidance — TGA's comprehensive document on Sponsor pharmacovigilance obligations.
• Adverse Event Management System (AEMS) — TGA's submission gateway for ICSRs; E2B(R3) format aligned with EU + ICH.
• Reporting timelines — Serious unexpected ADRs (SUSARs) within 15 calendar days of Sponsor awareness; serious expected ADRs in periodic safety updates; non-serious ADRs in annual periodic safety updates.
• Periodic Safety Update Report (PSUR) — required for prescription medicines + biologicals; TGA PSUR cycle aligned with EU EURD list where applicable.
• Risk Management Plan (RMP) — Australian-Specific Annex (ASA) to the Core RMP; required for new prescription medicines + significant lifecycle changes.
• Black Triangle Scheme — Australia is one of several countries operating an additional-monitoring (black triangle) scheme; product information for new active substances + biologicals + provisionally approved products carries a black triangle for a defined period.
• Database of Adverse Event Notifications (DAEN) — TGA's public-facing database of medicines + medical-device adverse event reports.
• Vanessa's Law-style mandatory hospital reporting — Australia operates a National Medical Devices Sentinel Notification System for healthcare settings.
• Medical device adverse event reporting — Sponsor reporting obligations for serious adverse events + serious public-health threats with TGA-mandated timelines aligned in substance with EU MDR Article 87 + FDA MDR.
• Pregnancy categories — Australian-specific pregnancy categorisation (A / B1 / B2 / B3 / C / D / X) used in Australian Product Information.
• Uniform Recall Procedure for Therapeutic Goods (URPTGA) — joint TGA / industry guidance on therapeutic-goods recalls with Class I / II / III risk-classification + execution timelines.

• COR — Comparable Overseas Regulator pathways for prescription medicines + biologicals; recognised CORs include EMA, FDA, Health Canada, Swissmedic, MHRA, Singapore HSA, PMDA + others. COR Pathway A enables most evaluation work to leverage the COR report (target 175 TGA working days vs 255 for standard).
• ACSS Consortium — Australia, Canada, Singapore, Switzerland, UK; harmonised assessment + work-sharing including the New Active Substance Work Sharing Initiative + generic + biosimilar work-sharing.
• MDSAP founding member — single QMS audit accepted by TGA + Health Canada + FDA + ANVISA + PMDA.
• PIC/S — TGA founding member 1995; mutual recognition of GMP inspections with 50+ PIC/S regulators.
• MRA partners — GMP-inspection mutual recognition with EU (since 1999), Switzerland, Singapore + others.
• ICMRA — International Coalition of Medicines Regulatory Authorities; collaborative work on pandemic response, supply chain, AI / ML regulation, biosimilars.
• Reference Regulator under MHRA IRP — UK's International Recognition Procedure (from 1 Jan 2024) recognises TGA decisions; UK applicants can submit Route A (60 UK days) or Route B (110 UK days) with the TGA assessment report.
• ANZ TPP (Australia New Zealand Therapeutic Products Agency) — long-standing aspirational joint regulator with NZ Medsafe; periodically advanced + paused; current state is parallel cooperation rather than merged authority.
• IMDRF — International Medical Device Regulators Forum; TGA is a founding member + actively contributes to UDI, SaMD, QMS, AI / ML harmonisation work products.

• Australian Sponsor not established or not properly contracted — non-Australian manufacturer treats global RA function as the Sponsor without formal Australian-based representation.
• Australian Product Information (PI) + Consumer Medicine Information (CMI) errors — Australian-specific content (PI structure, indication wording, pregnancy categorisation, Australian-relevant precautions) not aligned with the TGA-approved PI.
• COR submission errors — COR Pathway A submitted when adjustments are needed (should be Pathway B); CO report not submitted in full; bridging content insufficient.
• GMP Clearance lapse — non-Australian site supplying Australia without a current TGA GMP Clearance; importation refused at the border.
• Provisional Approval commitments delayed — confirmatory data not submitted in time, threatening extension or conversion to standard approval.
• AUST L compliance review failures — complementary-medicine claims outside the TGA-approved evidence + permitted-indication list discovered at post-listing compliance review; ARTG cancellation + recall.
• AUST L(A) evidence package thin — efficacy evidence for the assessed listed claim insufficient for the level of indication sought.
• Conformity Assessment certificate scope mismatch — manufacturer relies on a Conformity Assessment certificate that doesn't cover the specific device variant or indication.
• MDSAP scope gaps — MDSAP audit doesn't cover Australia regulatory requirements addendum; TGA requires supplementary audit.
• AusUDI implementation behind schedule — phased transitions not met per the 25 Feb 2021 rules; ARTG entry conditions breached.
• ICSR submission late — beyond the 15-day SUSAR timeline via AEMS.
• Australian-Specific Annex (ASA) to RMP not maintained — Australian risk-minimisation measures not reflected in the local RMP.
• Recall classification under URPTGA inconsistent with risk; communications to healthcare + retail not executed per the recall plan.
• Biological Class 1-4 framework misapplication — product positioned as Class 1 (lowest risk) when its actual classification + GMP scope requires higher-class controls.
• TGA Manufacturing Licence renewal lapse for Australian sites.

• Pre-submission meeting count + commitment-incorporation rate before standard / COR / Priority / Provisional submission.
• COR Pathway A vs B utilisation rate.
• Evaluation cycle time vs target (255 / 175 / 150 TGA working days by pathway).
• Provisional Approval commitment fulfilment vs timeline.
• AUST L compliance review pass rate.
• MDSAP + Conformity Assessment certificate continuity per device line.
• TGA GMP Clearance status per non-Australian Australia-supplying site.
• AEMS ICSR on-time submission rate.
• PSUR + ASA-to-RMP on-time submission rate.
• Recall classification + execution timeline under URPTGA.
• AusUDI implementation status per device line vs phased transition.
• Australian PI / CMI freshness + alignment with global core data sheet.

V5 Ultimate runs the GMP + QMS + pharmacovigilance evidence layer that sits beneath every TGA-regulated activity. Specifically:

• PIC/S GMP + Annex 11 control framework — computerised-systems lifecycle, electronic-record + electronic-signature controls aligned with the PIC/S + ICH expectations TGA Inspectorate enforces.
• MDSAP-ready QMS — single audit-evidence package mapping the QMS to ISO 13485 + TGA + Health Canada + FDA + ANVISA + PMDA requirements.
• Australian Sponsor workflow — Sponsor sign-off routing on ARTG variations, batch release, recalls, pharmacovigilance reports.
• ARTG submission packaging — eCTD with Australian-specific Module 1, Australian PI + CMI authoring, COR Pathway A / B bridging documentation.
• Australian PI + CMI authoring — controlled-content templates, version control, side-by-side comparison with global Core Data Sheet, TGA-format output.
• TGA GMP Clearance maintenance — non-Australian site evidence calendar, MRA / CV / TGA-inspection-route tracking, expiry-management alerts.
• AEMS / ICSR pipeline — E2B(R3) ICSRs from the complaint + adverse-event intake module submitted via AEMS on the 15-day / periodic timelines.
• Australian-Specific Annex (ASA) to RMP — version-controlled local-risk-minimisation document; aRMM implementation evidence including HCP letters, patient materials, controlled distribution.
• URPTGA recall execution — Class I / II / III triage with timeline-bound execution + healthcare + retail communication tracking.
• Provisional Approval commitment tracking — confirmatory study milestone calendar with go/no-go review checkpoints for conversion to standard registration.
• AusUDI implementation tracker — per device line, transition status against the 25 Feb 2021 rules + phased deadlines through 2026-2030.
• Black Triangle Scheme labelling control — additional-monitoring symbol applied to Australian PI / CMI for products subject to the scheme.
• AUST L self-certification workflow — claim + ingredient list checked against TGA-permitted indications + approved ingredients before ELF submission.